An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease

Part of paid clinical trials in Little Rock, Arkansas.

Sponsor
Amgen
Study ID
NCT07438405
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Thyroid Eye Disease

Eligibility Criteria

Sex
ALL
Age
18 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

  • AMG 732 — DRUG
    AMG 732 will be administered SC.

Study Details

The main objective of this trial is to assess the efficacy of AMG 732 in participants with thyroid eye disease (TED) who are defined as primary nonresponders or relapsed during the safety follow-up in the parent trial (NCT06401044).

Key Dates

Start date
May 7, 2026
Status verified
May 2026
Primary completion
Jan 29, 2028
Completion
Jul 14, 2028

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: AMG 732
    Participants will receive AMG 732 subcutaneously (SC)

Primary Outcome Measure

Number of Participants who are Proptosis Responders in the Trial Eye at Week 24 in Participants with TED who are Defined as Primary Nonresponders or Relapsed During the Safety Follow-up in the Parent Trial [ Time Frame: Week 24 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Applied Research Center of ArkansasLittle RockArkansas72205-

Find similar trials in Little Rock, AR

By research site
Applied Research Center of Arkansas· Little Rock, AR

Related Studies